Exploring the Anticancer Potential of Origanum majorana Essential Oil Monoterpenes Alone and in Combination against Non-Small Cell Lung Cancer

被引:6
|
作者
Arafat, Kholoud [1 ]
Al-Azawi, Aya Mudhafar [1 ]
Sulaiman, Shahrazad [1 ]
Attoub, Samir [1 ,2 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol & Therapeut, Coll Med & Hlth Sci, Al Ain 15551, U Arab Emirates
[2] United Arab Emirates Univ, ASPIRE Precis Med Res Inst Abu Dhabi, Al Ain 15551, U Arab Emirates
关键词
NSCLC; monoterpenes; terpinen-4-ol; sabinene hydrate; alpha-terpinene; gamma terpinene; survivin; tumor growth; IN-VITRO; CYTOTOXICITY; ANTIOXIDANT;
D O I
10.3390/nu15235010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Lung cancer is the second most commonly diagnosed cancer and has the highest mortality rate worldwide despite the remarkable advances in its treatment. Origanum majorana Essential Oil (OMEO) has been shown to be effective against non-small cell lung cancer (NSCLC) cells, decreasing their viability and colony growth in vitro, as well as inhibiting tumor growth in chick embryo chorioallantoic membranes (CAM) and nude mice in vivo. OMEO is mainly composed of four monoterpenes, namely terpinen-4-ol, sabinene hydrate, alpha-terpinene, and gamma-terpinene. In this study, we aimed to investigate the potential anticancer effects of these monoterpenes, either alone or in combination, on NSCLC. Our findings indicate that these four monoterpenes significantly decreased NSCLC cell viability in a concentration-dependent manner, reduced their colony growth in vitro, and also downregulated survivin expression in these cells. Moreover, different combined mixtures of these monoterpenes further enhanced their anticancer effects on cellular viability, with a terpinen-4-ol and sabinene hydrate combination being the most potent. We also found that terpinen-4-ol, in combination with sabinene hydrate, markedly enhanced the anticancer effect of the individual monoterpenes on NSCLC viability within a shorter treatment duration through, at least in part, survivin downregulation. Furthermore, this combination enhanced the inhibition of colony growth in vitro and the tumor growth of NSCLC cells xenografted onto chick embryo CAM in vivo. Altogether, our study highlights the potential of these monoterpenes for use in further pre-clinical investigations against various cancer hallmarks.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Combination of biological therapies in non-small cell lung cancer
    Bianco, R
    Damiano, V
    Tortora, G
    ANNALS OF ONCOLOGY, 2006, 17 : 52 - 54
  • [22] Combination of nivolumab with radiotherapy for non-small cell lung cancer
    Cihan, Y. B.
    ARCHIVES OF HELLENIC MEDICINE, 2022, 39 (06): : 857 - 858
  • [23] Combination therapy with gemcitabine in non-small cell lung cancer
    Mosconi, AM
    Crino, L
    Tonato, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : S14 - S17
  • [24] Chemical Constituents and Anticancer Activity of Curcuma zedoaria Roscoe Essential Oil against Non-Small Cell Lung Carcinoma Cells in Vitro and in Vivo
    Chen, Chien-chang
    Chen, Yuhsin
    Hsi, Yi-Ting
    Chang, Chih-Sheng
    Huang, Li-Fen
    Ho, Chi-Tang
    Way, Tzong-Der
    Kao, Jung-Yie
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2013, 61 (47) : 11418 - 11427
  • [25] The limits of surgical resection alone for non-small cell lung cancer
    Johnston, MR
    LUNG CANCER, 1997, 17 : S99 - S102
  • [26] Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer
    Danesi, R
    De Braud, F
    Fogli, S
    De Pas, TM
    Di Paolo, A
    Curigliano, G
    Del Tacca, M
    PHARMACOLOGICAL REVIEWS, 2003, 55 (01) : 57 - 103
  • [27] Activity of dianhydrogalactitol alone or with platinum drugs against non-small cell lung cancer cell lines.
    Steino, Anne
    He, Guangan
    Bacha, Jeffrey A.
    Kanekal, Sarath
    Brown, Dennis
    Siddik, Zahid Hussain
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer
    Fujie, Hitomi
    Tanaka, Toshiaki
    Tagawa, Masatoshi
    Kaijun, Niu
    Watanabe, Mika
    Suzuki, Takashi
    Nakayama, Katsutoshi
    Numasaki, Muneo
    CANCER SCIENCE, 2011, 102 (11) : 1977 - 1990
  • [29] ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
    Nensi, Shrestha
    Ashton, John
    CURRENT CANCER DRUG TARGETS, 2021, 21 (09) : 737 - 748
  • [30] Ipilimumab: its potential in non-small cell lung cancer
    Tomasini, Pascale
    Khobta, Nataliya
    Greillier, Laurent
    Barlesi, Fabrice
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (02) : 43 - 50